Literature DB >> 10697236

Cerebral atrophy in Cushing's disease.

N E Simmons1, H M Do, M H Lipper, E R Laws.   

Abstract

BACKGROUND: Cushing's disease causes significant pathological changes throughout the body as a result of elevated cortisol levels. Very few systematic investigations have focused on the morphologic effects of hypercortisolism on the central nervous system. The validity of using premature cerebral atrophy as a diagnostic tool for Cushing's disease remains unknown.
METHODS: This study includes 63 patients with Cushing's disease who were evaluated and treated at the University of Virginia Medical Center. Radiologists randomly compared these individuals with age- and sex-matched controls in a blinded protocol, assessing the degree of cerebral atrophy on computed tomography and magnetic resonance scans.
RESULTS: Patients with Cushing's disease showed significant premature atrophy when compared with controls. This trend continued after subdividing the groups based on age and duration of symptoms except in the following groups: age greater than 60, duration of symptoms less than 1 year, and symptoms lasting between 4-5 years.
CONCLUSIONS: Excluding the three aforementioned groups, the hypercortisolemic state manifested in patients with Cushing's disease promotes the premature development of cerebral atrophy, which can be identified on routine radiologic imaging and may assist in the clinical diagnosis of the condition.

Entities:  

Mesh:

Year:  2000        PMID: 10697236     DOI: 10.1016/s0090-3019(99)00197-4

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  26 in total

1.  MR quantitation of volume and diffusion changes in the developing brain.

Authors:  Lijuan Zhang; Kathleen M Thomas; Matthew C Davidson; B J Casey; Linda A Heier; Aziz M Uluğ
Journal:  AJNR Am J Neuroradiol       Date:  2005-01       Impact factor: 3.825

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Mapping cognitive and emotional networks in neurosurgical patients using resting-state functional magnetic resonance imaging.

Authors:  Michael P Catalino; Shun Yao; Deborah L Green; Edward R Laws; Alexandra J Golby; Yanmei Tie
Journal:  Neurosurg Focus       Date:  2020-02-01       Impact factor: 4.047

Review 4.  Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment.

Authors:  N Sonino; G A Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  White matter alterations in the brains of patients with active, remitted, and cured cushing syndrome: a DTI study.

Authors:  P Pires; A Santos; Y Vives-Gilabert; S M Webb; A Sainz-Ruiz; E Resmini; I Crespo; M de Juan-Delago; B Gómez-Anson
Journal:  AJNR Am J Neuroradiol       Date:  2015-04-30       Impact factor: 3.825

Review 6.  Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-07-03       Impact factor: 3.911

7.  Cortisol, depression and reduced cortico-cortical cross-talk in Cushing's syndrome.

Authors:  D J L G Schutter; J van Honk; E H F de Haan; A C van Huffelen; H P F Koppeschaar; H P F Koppeschar
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

Review 8.  Genomic and epigenomic mechanisms of glucocorticoids in the brain.

Authors:  Jason D Gray; Joshua F Kogan; Jordan Marrocco; Bruce S McEwen
Journal:  Nat Rev Endocrinol       Date:  2017-09-01       Impact factor: 43.330

9.  Adult attachment insecurity and hippocampal cell density.

Authors:  Markus Quirin; Omri Gillath; Jens C Pruessner; Lucas D Eggert
Journal:  Soc Cogn Affect Neurosci       Date:  2009-12-09       Impact factor: 3.436

Review 10.  Cushing's disease: the burden of illness.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Chiara Simeoli; Annamaria Colao
Journal:  Endocrine       Date:  2016-05-17       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.